Literature DB >> 21670086

Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?

Carlos L Arteaga1.   

Abstract

Inhibition of the HSP90 chaperone leads to degradation of the HER2 receptor. The HSP90 inhibitor tanespimycin in combination with trastuzumab is active in patients with HER2-overexpressing metastatic breast cancer. This combination is one of several HER2-targeted therapies that will significantly improve the outcome of patients with this subtype of breast cancer. ©2011 AACR.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21670086      PMCID： PMC3221729          DOI： 10.1158/1078-0432.CCR-11-1218

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.

Authors:  W Xu; E Mimnaugh; M F Rosser; C Nicchitta; M Marcu; Y Yarden; L Neckers
Journal:  J Biol Chem       Date:  2000-11-08       Impact factor: 5.157

Review 2.  Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.

Authors:  Joan T Garrett; Carlos L Arteaga
Journal:  Cancer Biol Ther       Date:  2011-05-01       Impact factor: 4.742

Review 3.  New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available.

Authors:  Vandana Abramson; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2011-01-19       Impact factor: 12.531

4.  Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

Authors:  José Baselga; Karen A Gelmon; Shailendra Verma; Andrew Wardley; Pierfranco Conte; David Miles; Giulia Bianchi; Javier Cortes; Virginia A McNally; Graham A Ross; Pierre Fumoleau; Luca Gianni
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

5.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Authors:  Kimberly L Blackwell; Harold J Burstein; Anna Maria Storniolo; Hope Rugo; George Sledge; Maria Koehler; Catherine Ellis; Michelle Casey; Svetislava Vukelja; Joachim Bischoff; Jose Baselga; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

6.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Authors:  Gunter von Minckwitz; Andreas du Bois; Marcus Schmidt; Nicolai Maass; Tanja Cufer; Felix E de Jongh; Eduard Maartense; Christoph Zielinski; Manfred Kaufmann; Wolfgang Bauer; Klaus H Baumann; Michael R Clemens; Ralph Duerr; Christoph Uleer; Michael Andersson; Robert C Stein; Valentina Nekljudova; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

7.  Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.

Authors:  Ching Ching Leow; Jon Chesebrough; Karen T Coffman; Christine A Fazenbaker; John Gooya; David Weng; Steve Coats; Dowdy Jackson; Bahija Jallal; Yong Chang
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

Review 8.  Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.

Authors:  Paul Workman; Francis Burrows; Len Neckers; Neal Rosen
Journal:  Ann N Y Acad Sci       Date:  2007-05-18       Impact factor: 5.691

9.  Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Authors:  Shanu Modi; Alison T Stopeck; Michael S Gordon; David Mendelson; David B Solit; Rochelle Bagatell; Weining Ma; Jennifer Wheler; Neal Rosen; Larry Norton; Gillian F Cropp; Robert G Johnson; Alison L Hannah; Clifford A Hudis
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

10.  Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.

Authors:  S Chandarlapaty; M Scaltriti; P Angelini; Q Ye; M Guzman; C A Hudis; L Norton; D B Solit; J Arribas; J Baselga; N Rosen
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867
View more
  15 in total

Review 1.  Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.

Authors:  Thuy Vu; Mark X Sliwkowski; Francois X Claret
Journal:  Biochim Biophys Acta       Date:  2014-07-25

2.  Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.

Authors:  Vito W Rebecca; Elizabeth Wood; Inna V Fedorenko; Kim H T Paraiso; H Eirik Haarberg; Yi Chen; Yun Xiang; Amod Sarnaik; Geoffrey T Gibney; Vernon K Sondak; John M Koomen; Keiran S M Smalley
Journal:  Mol Cell Proteomics       Date:  2014-04-23       Impact factor: 5.911

3.  The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.

Authors:  Kim H T Paraiso; H Eirik Haarberg; Elizabeth Wood; Vito W Rebecca; Y Ann Chen; Yun Xiang; Antoni Ribas; Roger S Lo; Jeffrey S Weber; Vernon K Sondak; Jobin K John; Amod A Sarnaik; John M Koomen; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2012-02-20       Impact factor: 12.531

4.  The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

Authors:  Alexandra Canonici; Zulfiqar Qadir; Neil T Conlon; Denis M Collins; Neil A O'Brien; Naomi Walsh; Alex J Eustace; Norma O'Donovan; John Crown
Journal:  Invest New Drugs       Date:  2018-02-02       Impact factor: 3.850

Review 5.  Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update.

Authors:  Daniel R Ciocca; Andre Patrick Arrigo; Stuart K Calderwood
Journal:  Arch Toxicol       Date:  2012-08-11       Impact factor: 5.153

Review 6.  Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.

Authors:  S V Alarcon; M Mollapour; M-J Lee; S Tsutsumi; S Lee; Y S Kim; T Prince; A B Apolo; G Giaccone; W Xu; L M Neckers; J B Trepel
Journal:  Curr Mol Med       Date:  2012-11-01       Impact factor: 2.222

7.  19-substituted benzoquinone ansamycin heat shock protein-90 inhibitors: biological activity and decreased off-target toxicity.

Authors:  Chuan-Hsin Chang; Derek A Drechsel; Russell R A Kitson; David Siegel; Qiang You; Donald S Backos; Cynthia Ju; Christopher J Moody; David Ross
Journal:  Mol Pharmacol       Date:  2014-03-28       Impact factor: 4.436

Review 8.  Hsp90 molecular chaperone inhibitors: are we there yet?

Authors:  Len Neckers; Paul Workman
Journal:  Clin Cancer Res       Date:  2012-01-01       Impact factor: 12.531

9.  Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.

Authors:  Loreta M Rodrigues; Yuen-Li Chung; Nada M S Al Saffar; Swee Y Sharp; Laura E Jackson; Udai Banerji; Marion Stubbs; Martin O Leach; John R Griffiths; Paul Workman
Journal:  BMC Res Notes       Date:  2012-05-23

Review 10.  Maximizing the Therapeutic Potential of HSP90 Inhibitors.

Authors:  Lisa M Butler; Roberta Ferraldeschi; Heather K Armstrong; Margaret M Centenera; Paul Workman
Journal:  Mol Cancer Res       Date:  2015-07-28       Impact factor: 5.852
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.